Physician profile
John D Mahan
NPI 1023002417
$88,975.50
in general payments reported to CMS, 2019-2025
15 companies · $8,772 in 2025
The $8,772 reported for 2025 was more than what 92% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,321 · 2020: $20K · 2021: $25K · 2022: $6,719 · 2023: $10K · 2024: $14K · 2025: $8,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,063 · Travel and Lodging: $1,916 · Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,944.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,062.50 |
| Travel and Lodging | $1,915.53 |
| Food and Beverage | $1,179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $33,906.72 | 2019-2022 | |
| Kyowa Kirin, INC. | $22,646.09 | 2023-2025 | Crysvita |
| Azurity Pharmaceuticals, INC. | $17,250.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $4,122.15 | 2025 | Empaveli |
| Vifor Pharma, INC. | $3,725.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,640.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,990.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $1,723.06 | 2019-2024 | Strensiq |
| Fresenius USA Marketing, INC. | $749.00 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $105.53 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $55.92 | 2022 | |
| Mallinckrodt Enterprises LLC | $33.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.78 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.